approval of the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.

Windlas Biotech Limited Reg. Off.: 40/1, Mohabewala Industrial Area Dehradun, Uttarakhand 248 110, India Tel.:+91-135-6608000-30, Fax:+91-135-6608199 Corp. Off.: 705-706, Vatika Professional Point, Sector-66, Golf Course Ext. Road, Gurgaon, Haryana 122 001, India Tel.:+91-124-2821030 CIN-L74899UR2001PLC033407 August 10, 2026 To To Listing / Compliance Department Listing / Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street, Mumbai – 400 001 Bandra Kurla Complex Bandra (E), Mumbai – 400 051 BSE CODE: 543329 NSE SYMBOL: WINDLAS Dear Sir/ Madam, Ref: Compliance of Regulation 33 and Regulation 30 of the SEBI (LODR) Regulations, 2015 Sub: Outcome of the Board Meeting held on August 10, 2026 We wish to inform you that the Board of Directors at its Meeting held on Monday, August 10, 2026, approved the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026. In this regard we enclose the following: i. Unaudited Standalone Financial Results for the Quarter ended June 30, 2026. ii. Limited Review Report of the Auditors on the Standalone Financial Results for the Quarter ended June 30, 2026. The meeting of the Board of Directors commenced at 2.30 P.M. and concluded at 3.15 P.M. Kindly take the same on record. Thanking you, Yours faithfully, For Windlas Biotech Limited Ananta Narayan Panda Company Secretary & Compliance Officer Encl: as above www.windlas.com J. C. BHALLA & CO. CHARTERED ACCOUNTANTS BRANCH OFFICE : B-5, SECTOR-6, NOIDA - 201 301 (U.P.) TEL. : +91 - 120 - 4241000, FAX : +91-120-4241007 E-MAIL : taxaid@jcbhalla.com Independent Auditor's Limited Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended The Board of Directors Windlas Biotech Limited 1. We have reviewed the accompanying statement of unaudited financial results of Windlas Biotech Limited ("the Company") for the quarter ended June 30, 2026 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended' 2. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. The preparation of the statement is in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind-AS) 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which itis to be disclosed, or that it contains any material misstatement. HEAD OFFICE : B-17, Maharani Bagh, New Delhi - 110065 5. Other Matter We draw attention to Note 9 to the accompanying Statement, which states that pursuant to the filing for dissolution of Windlas Inc., USA, a wholly owned non- operating subsidiary of the Company, with the Delaware Division of Corporations and pursuant to the Board Resolution dated February 5, 2026, the said subsidiary stands dissolved with effect from March 31, 2026. Accordingly, with effect from April 1, 2026, the Company is no longer required to prepare consolidated financial statements. Our conclusion is not modified in respect of this matter. For J C Bhalla & Co. Firm Regn. No. Anshuman Mallick Partner Membership No. 547’ UDIN: 94 S 370 :DI VMYXD&EH 320 Place: Noida Date : August 10, 2026 Windlas Biotech Limited CIN: L74899UR2001PLC033407 Registered office: 40/1 Mohabewala Industrial Area, SBI Road,Dehradun-248110 (Uttarakhand), India Telephone No: 0135-6608000| Email ID: cs@windlasbiotech.com| Website: www.windlasbiotech.com Statement of unaudited financial results for the quarter ended 30th June'2026 (All amounts in Indian Rupees in millions, unless otherwise stated) Quarter Ended Year Ended 30th June, 31st March, 2026 30th June, 31st March, Particulars 2026 (Audited) 2025 2026 (Unaudited) (refer note no 10) (Unaudited) (Audited) Revenue from Operations 2 ,480.99 2 ,384.99 2 ,100.90 9 ,040.89 Other Income 5 1.13 4 3.98 5 2.39 1 78.04 Total Income 2 ,532.12 2 ,428.97 2 ,153.29 9 ,218.93 Expenses Cost of Material Consumed 1 ,687.41 1 ,454.63 1 ,254.54 5 ,501.30 Changes in Inventories of Finished goods and Work-in-progress ( 160.12) 1 5.88 4 2.76 7 1.04 Employee Benefit Expenses 4 44.34 4 13.69 3 22.31 1 ,520.93 Finance Cost 1 6.50 1 4.75 1 0.57 4 8.25 Depreciation and Amortization expense 7 2.06 7 9.99 7 4.48 3 07.43 Other Expenses 2 42.57 2 48.41 2 16.05 9 00.67 Total Expenses 2 ,302.76 2 ,227.35 1 ,920.71 8 ,349.62 Profit before tax 2 29.36 2 01.62 2 32.58 8 69.31 Income tax expense Current tax 6 3.54 4 8.10 5 5.53 2 06.99 Deferred Tax ( 10.71) ( 6.64) 0 .40 ( 2.03) Total Tax Expense 5 2.83 4 1.46 5 5.93 2 04.96 Profit for the year 1 76.53 1 60.16 1 76.65 6 64.35 Other Comprehensive Income A (i) Items that will not be reclassified to profit or loss: Remeasurement of defined benefit plans- gain/(loss) ( 0.61) 1 .04 0 .48 1 .49 Income tax effect 0 .15 ( 0.27) ( 0.12) ( 0.38) Other Comprehensive Income for the year ( 0.46) 0 .77 0 .36 1 .11 Total Comprehensive Income for the year 1 76.07 1 60.93 1 77.01 6 65.46 Paid up equity share capital (Face value of Rs. 5/- per share) 1 03.18 1 05.53 1 04.80 1 05.53 Total Reserves - - - 5 ,702.80 Earnings per share*: Basic (in Rs.) 8 .46 7 .60 8 .43 3 1.59 Diluted (in Rs.) 8 .32 7 .50 8 .34 3 1.14 Face value per share (in Rs) 5 .00 5 .00 5 .00 5 .00 *EPS are not annualised Notes : 1.Theunauditedfinancialresultsofthecompanyforthequarterendedason30thJune,2026hasbeenpreparedasperregulation33ofthe SEBI LODR (Listing Obligation and Disclosure Requirements ) regulation 2015. 2.Thefinancialresults havebeen reviewed bytheaudit committeeand approved bytheboard of directors attheir meetingheld on 10th August , 2026 and limited review has been carried out by statutory auditors. 3.The financial results have been prepared in accordance with the Indian Accounting Standards notified under section 133 of the companies act, 2013, read with the companies (Indian accounting standards) Rules, 2015, as amended. 4. According to Indian Accounting Standard (Ind-AS) 108 on “Operating Segment” the Company has only one primarily reportable segment i.e. "Pharmaceuticals" Windlas Biotech Limited CIN: L74899UR2001PLC033407 Registered office: 40/1 Mohabewala Industrial Area, SBI Road,Dehradun-248110 (Uttarakhand), India Telephone No: 0135-6608000| Email ID: cs@windlasbiotech.com| W [Showing first 8,000 characters — download PDF for full document]